What I like about EASL is that it provides a worldview of hepatitis C and liver-related issues. This year’s conference was exceptional. There were thousands of posters and presentations from all over the world. Listed below are three posters I found interesting and provide a glimpse of hepatitis C in countries that are usually not covered in the press.
STUDY Abstract: THU-075 hepatitis C screening within the National Elimination Program in the country of Georgia – A. Gamkrelidze, et. al.
Summary: The country of Georgia is a testing ground for the elimination of hepatitis C (HCV). The prevalence of HCV is 7.7% and the government has started a campaign to identify 90% of people infected with hepatitis C and treat and cure 95%. There are 602 free testing centers across the country.
The testing results were available: as of November 2017, 1.2 million antibody screening tests have been conducted and 9.3% tested HCV antibody positive. The majority (79%) of positive results were among people aged 30-59 years old.
Note: They are also well on their way to treating many Georgians with DAA therapies. I will cover this in a separate HCV Advocate issue.
STUDY Abstract: THU-104 The first result from the general population hepatitis screening in Mongolia: 38% of 40– 65-year-olds screened and anti-HCV prevalence of 15.6% among 40– 65-year-olds – B. Dashtseren, et. al.
Summary: The goal in Mongolia is to test all Mongolians for HCV by 2018 and eliminate HCV by 2020. The estimated prevalence of HCV in Mongolia is 8.5%. The first stage started in June 2017 to test all adults aged 40-65-years of age. The number of people aged 40-65-years old who tested positive for HCV antibodies was 116,092 (15.9%).
STUDY Abstract: PS-090 Direct-acting antiviral treatment in sub-Saharan Africa: A prospective trial of ledipasvir/sofosbuvir for chronic hepatitis C infection in Rwanda (The SHARED Study) – N. Gupta, et. al.
Summary: The SHARED study was initiated to evaluate the safety and efficacy of ledipasvir/sofosbuvir (Harvoni). 300 adults with HCV genotype 1 and 4 were treated for 12 weeks. The majority of participants were women, and were genotype 4—47 pts (17%) had mixed genotypes 1 and 4. Ten percent were coinfected with HIV.
164 patients have completed treatment and had follow-up data. The cure rate was 87% (142 of 164 patients). The majority of treatment failures were in the people with mixed genotypes and high viral loads.Share This Page